Skip to Main Content
Contribute Try STAT+ Today

Six years after a national scandal erupted, a group of federal and state authorities have wrested a $40 million payout from the drug company once run by Martin Shkreli for drastically boosting the price of an old medicine and then concocting a scheme to illegally block competition. And his one-time friend and business partner, Kevin Mulleady, was banned from the pharmaceutical industry for seven years.

The infamous saga began when Vyera Pharmaceuticals, previously known as Turing Pharmaceuticals, bought Daraprim, a drug taken by HIV patients, and raised the price by more than 4,000% — from $17.50 a tablet to to $750. The move galvanized criticism of the pharmaceutical industry at a moment when the cost of prescription drugs was becoming a pocketbook issue for many Americans.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment